PMID- 28502502
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20210504
IS  - 1933-2874 (Print)
IS  - 1876-4789 (Linking)
VI  - 11
IP  - 2
DP  - 2017 Mar-Apr
TI  - Dapagliflozin in patients with type II diabetes mellitus, with and without 
      elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
PG  - 450-458.e1
LID - S1933-2874(17)30023-5 [pii]
LID - 10.1016/j.jacl.2017.01.018 [doi]
AB  - BACKGROUND: Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor 
      that improves glycemic control in patients with type II diabetes mellitus (T2DM) 
      by reducing renal glucose reabsorption. OBJECTIVE: The aim was to evaluate the 
      lipid effects of dapagliflozin 10 mg or placebo in patients with T2DM 
      with/without baseline elevated triglyceride and reduced high-density lipoprotein 
      (HDL) cholesterol levels. METHODS: This was a post hoc analysis of 10 phase 3, 
      placebo-controlled studies of dapagliflozin 10 mg (N = 2237) or placebo 
      (N = 2164) administered for 24 weeks in patients with T2DM. Patients with 
      elevated triglyceride (>/=150 mg/dL [1.69 mmol/L]) and reduced HDL cholesterol 
      levels (<40 mg/dL [1.04 mmol/L] in men; <50 mg/dL [1.29 mmol/L] in women) were 
      included (group A). The reference group (group B) included patients who did not 
      meet the defined lipid criteria. RESULTS: The effects of dapagliflozin on fasting 
      lipid profiles were generally similar in the 2 lipid groups (ie, groups A and B) 
      and, compared with placebo, were associated with minor increases in non-HDL 
      cholesterol, low-density lipoprotein, and HDL cholesterol levels. The effects on 
      triglyceride levels were inconsistent. The incidence of adverse events 
      (AEs)/serious AEs, and AEs of genital infection, urinary tract infection, volume 
      reduction, renal function, and hypoglycemia were similar in the 2 lipid groups. 
      CONCLUSION: Patients with T2DM treated with dapagliflozin experienced minor 
      changes in lipid levels; the changes were generally similar in the 2 lipid 
      groups. The clinical significance of these changes in lipids is unclear, 
      especially in view of the positive effects of dapagliflozin on other 
      cardiovascular disease risk factors.
CI  - Copyright (c) 2017 National Lipid Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Bays, Harold E
AU  - Bays HE
AD  - Louisville Metabolic and Atherosclerosis Research Center Inc., Louisville, KY, 
      USA. Electronic address: hbaysmd@outlook.com.
FAU - Sartipy, Peter
AU  - Sartipy P
AD  - Global Medicines Development, CVMD, AstraZeneca, Gothenburg, Sweden; Systems 
      Biology Research Center, School of Bioscience, University of Skovde, Skovde, 
      Sweden.
FAU - Xu, John
AU  - Xu J
AD  - Biometrics and Information Sciences, AstraZeneca, Gaithersburg, MD, USA.
FAU - Sjostrom, Carl David
AU  - Sjostrom CD
AD  - Global Medicines Development, CVMD, AstraZeneca, Gothenburg, Sweden.
FAU - Underberg, James A
AU  - Underberg JA
AD  - Department of Medicine, NYU School of Medicine & NYU Center for Prevention of 
      Cardiovascular Disease, New York, NY, USA.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
DEP - 20170210
PL  - United States
TA  - J Clin Lipidol
JT  - Journal of clinical lipidology
JID - 101300157
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Triglycerides)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzhydryl Compounds/*pharmacology/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Female
MH  - Glucosides/*pharmacology/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - Lipoproteins, HDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/*blood
MH  - Young Adult
OTO - NOTNLM
OT  - Cardiovascular
OT  - Dapagliflozin
OT  - Dyslipidemia
OT  - SGLT2 inhibitors
OT  - Type II diabetes mellitus
EDAT- 2017/05/16 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/05/16 06:00
PHST- 2016/11/22 00:00 [received]
PHST- 2017/01/24 00:00 [revised]
PHST- 2017/01/26 00:00 [accepted]
PHST- 2017/05/16 06:00 [entrez]
PHST- 2017/05/16 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - S1933-2874(17)30023-5 [pii]
AID - 10.1016/j.jacl.2017.01.018 [doi]
PST - ppublish
SO  - J Clin Lipidol. 2017 Mar-Apr;11(2):450-458.e1. doi: 10.1016/j.jacl.2017.01.018. 
      Epub 2017 Feb 10.